The Centre retains a strong focus on vaccine epidemiology across multiple disease areas, which span the whole development pipeline from discovery science, clinical trials, through to impact monitoring and programme optimisation.

At the discovery stage, there is a strong focus on the early life intestinal microbiome and its relationship with vaccine-induced immunity for poliovirus, rotavirus, enterovirus and typhoid. At the intermediate stage, we inform the development of new prevention tools, including new vaccines against sexually transmitted infections, by informing the design, conduct, and interpretation of pivotal clinical trials, and defining the desired product characteristics needed to meet priority public health goals to support investment in product development.

We continue to undertake a substantial portfolio of research on the public health impact and evaluation of vaccines post-licensure, including vaccination against HPV, HIV and other sexually transmitted infections and support for the Global Polio Eradication Initiative and GAVI on the public health impact and cost-effectiveness of malaria and yellow fever vaccines.

The Centre conducts extensive research into interventions which aim to improve population health, including mass drug administration programmes, combination of biological, behavioural and structural prevention interventions, and health education initiatives to promote behaviour modification and infectious disease vector control and elimination techniques.

Researchers combine state-of-the-art mathematical, statistical and epidemiological methods with high-quality data to answer a wide range of policy relevant questions.

Vaccine and intervention research conducts multidisciplinary and collaborative research with a broad range of international research groups, centers and institution and stakeholders, including the World Health Organization (WHO), HIV Prevention Trial Network (HPTN) and Centers for Disease Control and Prevention (CDC), in order to understand and reduce the burden of major infections and diseases and accelerate the development and efficient implementations of prevention interventions